Advaxis (ADXS) : The bears are holding on to their shorts in Accenture Plc with 3 more days remaining for them to cover their positions. The bearish positions have increased from 8,182,438 on Jul 29, 2016, to 9,718,568, on August 15, 2016. Daily, 2,801,697 shares are traded, which shows the high interest of the traders in the stock. The net addition of short open interest is 1,536,130 shares, which is an increase of just 18.8%. The total short interest of 32.6% of the float indicates that there arent many bears on this stock at the current prices. The short interest information was released on Wednesday Aug 24th after the market close.
Advaxis (NASDAQ:ADXS): The stock opened at $13.37 on Wednesday but the bulls could not build on the opening and the stock topped out at $13.51 for the day. The stock traded down to $12.04 during the day, due to lack of any buying support eventually closed down at $12.14 with a loss of -9.06% for the day. The stock had closed at $13.35 on the previous day. The total traded volume was 1,420,425 shares.
In a related news, The director, of Advaxis, Inc., Berman Richard J had unloaded 33,761 shares at $15.44 per share in a transaction on August 8, 2016. The total value of transaction was $521,270. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Advaxis, Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on developing various cancer immunotherapies that use the bodys natural immune system to redirect the immune response to kill cancer. Its Lm Technology is a cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen, and neutralizes regulatory T cells and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Its Lm Technology immunotherapy, axalimogene filolisbac (ADXS-HPV), targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase II in invasive cervical cancer, Phase I/II in head and neck cancer, and Phase I/II in anal cancer. It has preclinical program with immunotherapies in development for cancers and infectious diseases.